Literature DB >> 8472903

Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin.

E S Cahill1, D T O'Hagan, L Illum, K Redhead.   

Abstract

Intra-nasal immunization of mice with purified Bordetella pertussis filamentous haemagglutinin (FHA) or a crude cell sonicate was shown to protect against subsequent B. pertussis aerosol challenge. Immunization with FHA was found to be the most effective and resulted in complete clearance of the bacterial infection from the lungs within 14 days. Serum IgG and lung IgA anti-FHA antibodies were detectable within 4 weeks of the first immunization and anamnestic responses were seen following secondary immunization and subsequent challenge with B. pertussis. Nasal administration of pertussis antigens is a route which induces good systemic serum, as well as local secretory, antibody responses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472903     DOI: 10.1111/j.1574-6968.1993.tb06032.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  11 in total

1.  Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.

Authors:  Zhang Jinyong; Zhang Xiaoli; Zhang Weijun; Guo Ying; Guo Gang; Mao Xuhu; Zou Quanming
Journal:  Mol Biol Rep       Date:  2010-09-28       Impact factor: 2.316

2.  Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; E E Moran; T Larsen; W D Zollinger
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

4.  Genome rearrangements, deletions, and amplifications in the natural population of Bartonella henselae.

Authors:  Hillevi Lindroos; Olga Vinnere; Alex Mira; Dirk Repsilber; Kristina Näslund; Siv G E Andersson
Journal:  J Bacteriol       Date:  2006-08-25       Impact factor: 3.490

5.  Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.

Authors:  S Alonso; K Pethe; N Mielcarek; D Raze; C Locht
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 6.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.

Authors:  Ahmad H Hussein; Elisabeth M Davis; Scott A Halperin; Song F Lee
Journal:  Infect Immun       Date:  2007-08-27       Impact factor: 3.441

8.  Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.

Authors:  D H Jones; B W McBride; C Thornton; D T O'Hagan; A Robinson; G H Farrar
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

9.  Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.

Authors:  Sylvie Alonso; Nathalie Reveneau; Kévin Pethe; Camille Locht
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.

Authors:  E J Ryan; E McNeela; G A Murphy; H Stewart; D O'hagan; M Pizza; R Rappuoli; K H Mills
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.